Fortifruitssp. z o.o.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2021-03-01
Share capital
5 000,00 PLN
Activity description

Fortifruits offers tools to improve the color of fruit for processing and storage systems that extend the shelf life of fresh fruit. It produces enhanced blueberry and raspberry extracts for food processing, supplements, and pharmaceutical ingredients; the extracts contain over 60% more polyphenols and antioxidants than extracts on the market.

Registered address
ul. Jana I Jędrzeja Śniadeckich 20D/7, 35-006 Rzeszów, Poland
Website
fortifruits.comWebsite active

Financials

Revenue history (in k)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue
This companyUSD 10.69kMedianUSD 782.27kAverageUSD 24.03m
Net profit
This companyUSD 6.81kMedianUSD 7.91kAverageUSD 2.59m
Operating costs
This companyUSD 3.20kMedianUSD 723.93kAverageUSD 19.92m
Assets
This companyUSD 293.21kMedianUSD 800.34kAverageUSD 29.11m

Bank accounts

Registered as a VAT taxpayer on 2026-05-18.

No bank accounts reported to the VAT Taxpayer Register.

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

Public aid

10 public aid cases recorded, with a total value of $224,447.

PurposeGross amount
De minimis aid (in accordance with Commission Regulation 2023/2831)
$4,322
De minimis aid (in accordance with Commission Regulation 2023/2831)
$20,730
De minimis aid (in accordance with Commission Regulation 2023/2831)
$4,018

European Funds

ProjectEU co-financing
Wprowadzenie na rynek innowacji produktowej - ekstraktów z owoców miękkich o podwyższonej zawartości antyoksydantów do produkcji suplementów diety, przemysłu spożywczego, farmaceutycznego.
$167.2K

Tenders

No recorded participation in tenders.

Authorized Representatives

Lesław Jan Ślisz – President of the Management Board

Manner of representation

In the case of a one-person management board, the member of the management board makes declarations on behalf of the company. In the case of a management board consisting of two or more persons, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations on behalf of the company.

Ownership

OwnerSharesShare valueStake
Maciej Jerzy Balawejder (48)
10$135.0610%
Lesław Jan Ślisz (63)
90$1,215.5690%

Beneficial owners

Person

Competitors

Name
Biovitalium Polskasp. z o.o.
LideoS.A.
Munar PharmaS.A.
Akademia Boreliozysp. z o.o.
BIO Animalisp. z o.o.
Ampliconsp. z o.o.
Xenira Pharmaceuticalssp. z o.o.
Sanford Biotechsp. z o.o.
Vaduse Dermatologiesp. z o.o.
IMP & Csp. z o.o.

Change history

DateEvent
2026-10-15Address change
2021-03-01Entered in the register

FAQ

Last updated: 2026-10-15